Sugi Predict

Sugi Predict / Compounds / SCHEMBL473919

SCHEMBL473919

SCHEMBL473919

COC(=O)c1cnc(Cl)c(Cl)c1

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.51
▸ MAPK1 P28482 5/20 0.51
▸ TDP1 Q9NUW8 3/20 0.51
▸ L3MBTL1 Q9Y468 3/20 0.51
▸ KMT2A Q03164 2/20 0.49
▸ ATM Q13315 1/20 0.49
▸ POLB P06746 2/20 0.47
▸ MAPT P10636 1/20 0.47
▸ GAA P10253 1/20 0.46
▸ APEX1 P27695 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ P2RY12 Q9H244 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ RXFP1 Q9HBX9 1/20 0.45
▸ PSMD14 O00487 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29726958 1.00 ALDH1A1 (0.51) ALDH1A1MAPK1TDP1L3MBTL1KMT2A
SCHEMBL17294344 0.84 ATM (0.51) ALDH1A1MAPK1TDP1L3MBTL1ATM
SCHEMBL3520084 0.84 MAPK1 (0.47) ALDH1A1MAPK1TDP1L3MBTL1ATM
SCHEMBL198706 0.84 MAPK1 (0.47) ALDH1A1MAPK1TDP1L3MBTL1KMT2A
SCHEMBL3655489 0.84 MAPK1 (0.47) ALDH1A1MAPK1TDP1L3MBTL1ATM
SCHEMBL30331909 0.84 ATM (0.51) ALDH1A1MAPK1TDP1L3MBTL1ATM
SCHEMBL336046 0.84 ATM (0.51) ALDH1A1MAPK1TDP1L3MBTL1ATM
SCHEMBL981603 0.84 KDM4E (0.53) ALDH1A1MAPK1TDP1L3MBTL1KMT2A
SCHEMBL24213965 0.82 MAPK1 (0.46) ALDH1A1MAPK1TDP1L3MBTL1KMT2A
SCHEMBL2346041 0.82 KDM4E (0.49) ALDH1A1MAPK1L3MBTL1KMT2AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612407-B2 Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist BEONE MEDICINES I GMBH (CH) 2026-04-28 — — US disclosed
US-12600716-B2 Compounds for modulating activity of FXR and uses thereof GANNEX PHARMA CO. LTD. (CN) 2026-04-14 — — US disclosed
EP-4073070-B1 COMPOUNDS FOR MODULATING ACTIVITY OF FXR AND USES THEREOF GANNEX PHARMA CO LTD (CN) 2026-02-18 — — EP disclosed
WO-2025125666-A1 SUBSTITUTED IMIDAZOLES AS INHIBITORS OF NAV1.8 Grünenthal GmbH (DE) 2025-06-19 — — WO disclosed
US-20250121073-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-04-17 — — US disclosed
US-12150995-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-11-26 — — US disclosed
US-20240360124-A1 Bromodomain Inhibitors ABBVIE INC. (US) 2024-10-31 — — US disclosed
US-20240360117-A1 BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS ENANTA PHARM INC (US) 2024-10-31 — — US disclosed
WO-2024074611-A1 PRMT5 INHIBITORS Ryvu Therapeutics S.A. (PL) 2024-04-11 — — WO disclosed
CN-113072542-B ROR gamma t inhibitor and preparation method and application thereof 广东东阳光药业股份有限公司 2024-04-05 — — CN disclosed
WO-2004002939-A2 AMINOALCOHOL DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-01-08 — — WO disclosed
US-20040006143-A1 For therapy of urinary incontinence FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-01-08 — — US disclosed
WO-2003051276-A2 THERAPEUTIC HETEROCYCLES ASTRAZENECA AB (SE) 2003-06-26 — — WO disclosed
EP-1276726-A2 SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS Abbott Laboratories (US) 2003-01-22 — — EP disclosed
US-20020019527-A1 Substituted phenyl farnesyltransferase inhibitors ABBOTT LABORATORIES 2002-02-14 — — US disclosed
WO-2001081316-A2 SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS ABBOTT LABORATORIES (US) 2001-11-01 — — WO disclosed
US-6169183-B1 REACTING 2,3-DIHALOPYRIDINE WITH CARBON MONOXIDE AND ALKANOL IN PRESENCE OF WEAK BASE AND COMPLEX OF PALLADIUM WITH SPECIFIED BIS(DIPHENYLPHOSPHINE), WHEREIN REACTION IS STOPPED AS SOON AS MAXIMUM CONCENTRATION OF ESTER IS ACHIEVED LONZA, LTD. (CH) 2001-01-02 — — US disclosed
US-6162921-A Process for preparing pyridinecarboxylic esters LONZA, LTD (CH) 2000-12-19 — — US disclosed
US-6022973-A Process for preparing pyridinecarboxylic esters LONZA LTD. (CH) 2000-02-08 — — US disclosed
US-5925765-A Process for preparing pyridinecarboxylic esters LONZA AG (CH) 1999-07-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12600716-B2 Compounds for modulating activity of FXR and uses thereof FXR1, NR1H4, FXR2 ALDH1A1 2458/4885MAPK1 1428/4885TDP1 4511/4885
US-20250121073-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 ALDH1A1 2776/4885MAPK1 2017/4885TDP1 236/4885
US-12612407-B2 Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist TLR7, TLR8, TLR1 ALDH1A1 1253/4885MAPK1 537/4885TDP1 2041/4885
US-12150995-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 ALDH1A1 2776/4885MAPK1 2017/4885TDP1 236/4885
US-20240360117-A1 BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS GABRA5, GABRA1, GABBR2 ALDH1A1 621/4885MAPK1 2860/4885TDP1 3446/4885
US-20040006143-A1 For therapy of urinary incontinence H1-0, HRH2, H1-2 ALDH1A1 1320/4885MAPK1 2563/4885TDP1 1459/4885
US-20020019527-A1 Substituted phenyl farnesyltransferase inhibitors FNTA, FNTB, SLC10A1 ALDH1A1 385/4885MAPK1 1124/4885TDP1 1874/4885
US-20240360124-A1 Bromodomain Inhibitors BRD4, BRD3, BRD1 ALDH1A1 3060/4885MAPK1 882/4885TDP1 758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.